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Background: Limited national data exists on the prevalence and distribution of underlying 
conditions among COVID-19 deaths between sexes and across age groups. 
Methods: All adult (≥18 years) deaths recorded in England and Wales (1st March 2020 to 
12th May 2020) were retrospectively analyzed. We compared 1) the prevalence of underlying 
health conditions between COVID and non-COVID related deaths during the COVID-19 
pandemic and 2) the age-standardized mortality rate (ASMR) of COVID-19 compared with 
other primary causes of death, stratified by sex and age group.
Results: Of 144,279 adult deaths recorded during the study period, 36,438 (25.3%) were 
confirmed COVID cases. Women represented 43.2% (n=15,731) of COVID deaths compared 
to 51.9% (n=55,980) in non-COVID deaths. Overall, COVID deaths were younger non-
COVID deaths (82 vs. 83 years). ASMR of COVID-19 was higher than all other common 
primary causes of death, across age groups and sexes, except for cancers in women between 
the ages of 30-79 years. A linear relationship was observed between ASMR and age amongst 
COVID-19 deaths, with persistently higher rates in men than women across all age groups. 
The most prevalent reported conditions were hypertension, dementia, chronic lung disease 
and diabetes, and these were higher amongst COVID deaths. Pre-existing ischemic heart 
disease was similar in COVID (11.4%) and non-COVID (12%) deaths. 
Conclusions: In a nationwide analysis, COVID-19 infection was associated with higher age-
standardized mortality than other primary causes of death, except cancer in women of select 
age groups. COVID-19 mortality was persistently higher in men and increased with advanced 
age. 
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More than 12 million patients worldwide have been infected with the severe acute 
respiratory syndrome coronavirus (SARS-CoV-2), resulting in the illness referred to as 
COVID-19.1 The United Kingdom (UK) has the second highest recorded number of deaths in 
the world after the US, with 39,728 deaths recorded as of 6th June 2020. 2 3
Age and comorbidities such as hypertension,  diabetes and ischemic heart disease 
(IHD) are strong predictors of adverse outcomes and mortality in people infected with 
COVID-19. 4 5 6 Furthermore, differences in COVID-19 survival has been observed between 
sexes, with females shown to have better outcomes. Several hypotheses have been proposed 
as an explanation of the latter, including biological (genetic and hormonal) differences 
between sexes as well as lower burden of comorbidity in females.4-8 Detailed data concerning 
underlying conditions is limited, with data from New York state reporting that 89.7% of 
fatalities attributed to COVID-19 had at least one comorbidity, most commonly hypertension, 
diabetes and hyperlipidemia.9 In the UK 91% of COVID-19 deaths in March 2020 had at 
least one pre-existing condition, with ischemic heart disease the most common (14%).10 
There is inconclusive evidence, however, on how the distribution of underlying conditions 
varies by sex and age in those that have died from COVID-19. 11-13 Furthermore, it is unclear 
as to how the underlying conditions in COVID-19 deaths differ from those in similar age/sex 
groups that have died from non-COVID related causes. 
Therefore, we investigated the pre-existing conditions in adults (≥18 years) who had 
died from COVID-19 in England and Wales between 1st March 2020 and 12th May 2020, 
stratified by sex and age group, and compare this with patients whose death was not 
attributed to COVID-19. 
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Data Source, Study Design and Population
This cross-sectional study included records of all adult (aged ≥18 years) deaths 
between 1st March 2020 and 12th May 2020 in England and Wales were collected from the 
Office for National Statistics (ONS) Civil Registrations of Death dataset and stratified 
according to COVID-19 status. 2 Children and adolescents aged below 18 years were 
excluded for the purpose of this analysis since their susceptibility to death from COVID-19 is 
significantly lower than adults, and the pattern of their causes of death vary to those in adults. 
14 The process of death certification and registration is a legal requirement in the United 
Kingdom where a doctor who has seen the deceased within the last 14 days of life must 
complete a Medical Cause of Death Certificate unless a post-mortem examination is planned. 
During the COVID-19 pandemic, the 14-day requirement was temporarily extended to 28 
days allowing for the exceptional circumstances. The ONS dataset includes information 
concerning the deceased’s age, sex, registration office (town or city), primary cause of death 
as well as up to 15 supplementary codes for their underlying conditions. A total of 900 
patients younger than 18 years of age were excluded. There were no other inclusion or 
exclusion criteria. The International Classification of Diseases, tenth revision (ICD-10) codes 
were used to extract data on COVID-19 (as the primary cause of death), pulmonary 
embolism, pre-existing IHD, heart failure, dementia, chronic kidney disease (CKD), 
hypertension, chronic lung disease, diabetes, liver, peripheral vascular disease (PVD), 
valvular heart disease, major bleeding, cancers, stroke (ischemic and hemorrhagic), acute 
coronary syndrome (ACS) and infective endocarditis. A full list of diagnosis codes used in 
the study is provided in Supplementary Table S1.
Statistical Analysis
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We compared the reported underlying acute and chronic conditions between patients 
with and without confirmed COVID-19 as the underlying primary contributory cause, 
stratified according to sex, and age band (18-29, 30-39, 40-49, 50-59, 60-69, 70-79, 80-89 
and ≥90 years). Age was not normally distributed and therefore summarized using median 
and interquartile range (IQR) and compared using the Kruskal-Wallis test. Categorical 
variables were summarized as percentages and analyzed using the chi squared (X2) test or 
Fisher’s exact test, where appropriate. Age-standardized mortality rates (ASMR), expressed 
as rates per 100,000 capita, were calculated for each age band based on the mid-2019 
population census for England and Wales. 15Statistical analyses were performed using Stata 
16 MP (College Station, TX).
Ethical Approval
This work was endorsed by the Scientific Advisory Group for Emergencies (SAGE), 
the body responsible for ensuring timely and coordinated scientific advice is made available 
to UK government decision makers. SAGE supports UK cross-government decisions in the 
Cabinet Office Briefing Room (COBR)) and by NHS England, which overseas 
commissioning decisions in the NHS, and NHS Improvement, which is responsible for 
overseeing quality of care in NHS hospitals.
Results
A total of 36,438 adult COVID-19 deaths were recorded in England and Wales 
between 1st March and 12th May 2020, of which 20,707 (56.8%) were in men and 15,731 
(43.2%) in women. The first death due to COVID-19 infection in the United Kingdom was 
recorded on 2nd March 2020. Over the same period a total of 107,859 non-COVID related 
deaths were recorded, including 51,879 (48.1%) in men and 55,980 (51.9%) in women. The 
median age of COVID-19 deaths was lower than that in non-COVID related deaths (82 
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(73,88) vs. 83 (74, 89) years). Overall, women were older in the COVID and non-COVID 
groups (84 (76, 90) vs. 80 (72, 87) years, p<0.001). 
The majority of death were observed among people aged 80-89 years (COVID: 
38.9%, non-COVID: 36.4%, Table 1). ASMR increased with age in both groups and were 
consistently higher for all age bands for non-COVID compared with COVID deaths. The 
ASMR was 61.4 per 100,000 population in the 60-69 age group for COVID deaths and 172.5 
per 100,000 population for non-COVID deaths. The absolute number of COVID-19 deaths 
was higher for men than women throughout the study period (Figure 1), with peak mortality 
observed between the 4th and 20th April 2020. The ASMR was approximately two-fold higher 
in men compared to women across all age groups for COVID-19 related deaths. (Table 1, 
Figure 2) A similar pattern was observed in the non-COVID group, albeit with less 
pronounced sex differences in ASMR.  Overall, the most common cause of death in younger 
age groups (<60 years) was cancer, whereas the most common causes of death in older age 
groups (>80 years) were dementia, cancer and old age (Table 2). However, ASMR of 
COVID-19 was higher than all other primary causes of death for people without COVID-19 
across all age groups and sexes, with the exception of cancer deaths for women aged 30-79 
years. The highest number of COVID-19 deaths was in London (total/male/female: 7,510, 
4,519, 2,991). (Table S2, Figure S1)
Approximately a third of individuals had no underlying chronic conditions in the non-
COVID (29.9%) and COVID groups (31.8%), and close to one in ten patients with COVID-
19 and non-COVID-19 deaths had three or more underlying conditions (10.4% vs. 9%). 
(Table 3, Figure 3) The rate of reported underlying chronic conditions was generally higher 
in COVID than non-COVID deaths, with the most prevalent reported conditions being 
hypertension (COVID vs. non-COVID: 19.0% and 11.2%), dementia (COVID vs. non-
COVID: 18.8% vs. 15.9%), chronic lung disease (COVID vs. non-COVID: 15.6% vs. 11.4%) 
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and diabetes (COVID vs. non-COVID: 15.2% vs. 8.1%). The rates of pre-existing IHD were 
similar in COVID (11.4%) and non-COVID (12%) deaths, although lower reported rates of 
cancers (7.8% vs. 23.4%) were observed amongst patients with reported COVID deaths. 
(Table 3) The prevalence of pre-existing IHD appeared to be significantly lower in men in 
the COVID-19 vs the non COVID-19 deaths among those aged <60 years but was similar for 
all other age groups. (Supplementary Tables S3A and S3B)
 Overall, women were more likely to have no underlying chronic conditions compared 
with men in both COVID and non-COVID groups (COVID: 33.6% vs. 30.5%, non-COVID: 
31.1% vs. 28.6%, Table 3, Figures 3 and 4). Amongst COVID-19 deaths, women had higher 
rates of dementia (21.2% vs. 17%, p<.001) as underlying conditions compared with men 
whilst men had higher rates of pre-existing IHD (14.1% vs. 7.9%), CKD (11.4% vs. 9.5%), 
hypertension (20.1% vs. 17.4%), diabetes (17.1% vs. 12.8%) compared with women (p<.001 
for all). There was no difference in the rates of underlying cancer, liver disease, pulmonary 
embolism and valvular heart disease betwee  sexes. While this pattern was generally 
consistent across the age groups, the rates of certain underlying conditions were higher for 
the younger age bands (Table S3A and S3B, Figure 4) Pulmonary embolism was more 
frequently reported in <60 and 60-69 age deciles, more so in men than women (<60 years: 
3.0% vs. 2.6%, 60-69 years: 2.9% vs. 1.8%, p<.001 for both). Individuals in the younger age 
deciles were also more likely to have cancer with higher rates observed in women compared 
to men (<60 years: 12.5% vs. 7.4%, 60-69 years: 14% vs. 10%, p<.001 for both). 
Discussion
This national study is the first to report detailed, patient-level data about the 
prevalence of underlying conditions according to COVID-19 status in England & Wales 
during the COVID-19 pandemic. We found that the age-standardized mortality rate for 
COVID-19 was higher than that from all common primary causes of death in non-COVID 
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patients, across all age groups and sexes, except for cancers in women between the ages of 
30-79 years. Second, we show that age standardized mortality was consistently higher for 
men than women for COVID-19 deaths by a factor of almost 2 across age groups. Finally, we 
provide a contrast of the distribution of underlying acute and chronic conditions between 
COVID and non-COVID related deaths, and report that hypertension, chronic lung diseases 
and diabetes were more commonly observed in COVID-19 deaths whereas cancers where 
more commonly observed in non-COVID deaths.
The greatest proportion of COVID deaths in England and Wales were observed in the 
70-79 and 80-89 age groups, with the median age being 82 years. The median age of death in 
Italy was 81 years, based on 31,096 deaths (as of May 21st, 2020), which is similar to our 
findings. Their report demonstrates that the highest number of deaths was observed in the 80-
89 years group (n=12,729/31, 096), followed by 70-79 years (n=8466) and ≥90 years 
(n=5227), however age standardized mortality rates were not presented which makes 
interpretation of data difficult, particularly when comparing with non-COVID deaths, or data 
derived from other countries. 16 Similarly, data from the National Center for Health Statistics 
(NCHS) as of 13th May 2020 demonstrates that mortality was highest in the 75-84 and ≥85-
year groups (27.2% and 31.8%, respectively) in the United States but, again they do not 
present age-adjusted figures.17 
The majority of recent studies have focused on the crude mortality or case-fatality 
rates of COVID-19. 18-21 The latter is a proportion of the cumulative reported number of 
deaths by the cumulative number of reported cases and can be misleading since there is often 
a lag in the manifestation of symptoms, testing for disease and reporting of the number of 
cases, meaning that the true case fatality rate is often underestimated as demonstrated with 
previous epidemics. 22, 23 Age-standardized mortality rates take in to account differences in 
the age structure of a population and allow a more direct comparison of underlying 
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conditions especially when these vary by age. Whilst there have been several reports about 
mortality during the COVID-19 pandemic, these have either not been derived from national 
populations or have not compared mortality rates with other causes of death within the 
population. 17, 19, 24-27 Our analysis, which provides full population coverage of all deaths in 
England and Wales, is the first to demonstrate that the age standardized mortality rate of 
COVID is significantly higher than that of any other primary cause of death in non-COVID 
subjects throughout the same period. This finding was consistent across all age groups and in 
both sexes, with the exception of women between 30-79 years whose mortality from cancer 
was comparable to that from COVID. 
Our findings suggest that age-standardized mortality in men was almost double 
compared to that of women across all age groups, despite crude death rates suggesting a 
significantly higher proportion of women ≥90 years dying from COVID-19 compared with 
men. Our crude findings are consistent with reports in the US, which show 41.7% of female 
deaths were amongst those 85 years and older compared to only 23.9% in men, with higher 
mortality in younger male age groups compared to women. 17 Similarly, data on COVID-
related deaths in Italy (n=31,096) demonstrates higher mortality in men than women across 
all age deciles except ≥90 years where mortality was higher than in women. 16 However, 
neither analyses provided an adjustment for age, which makes comparisons between sexes 
challenging. 
Differences in outcomes between sexes could be explained by the greater number of 
reported underlying conditions in men compared to women as demonstrated in our analysis. 
Another proposed hypothesis relates to the circulating level of angiotensin-converting 
enzyme 2 (ACE2), the main host cell receptor towards which SARS-CoV-2 has been shown 
to have significantly high affinity, which has been shown to be greater in men than women, 
and in adults compared to children. 28 5, 29 Furthermore, women are believed to have a better 
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immune response against viral infections compared with men, primarily due to higher levels 
of estrogen, which is also believed to directly suppress viral replication.7, 8, 13 The decline in 
levels of estrogen with advanced age, albeit with higher level in females throughout, could 
also explain the higher rate of mortality elder subjects. 6 
Our analysis suggests that a small proportion of COVID-19 deaths experienced acute 
events such ACS, acute stroke and pulmonary embolism, and these were lower than in non-
COVID deaths. It is difficult to compare these findings to other studies due to limited data on 
the acute conditions reported in COVID deaths from other countries, or whether there may 
have been an element of reporting bias, where acute events were reported as COVID deaths. 
Previous studies have suggested a high prevalence of certain comorbidities such as 
hypertension and ischemic heart disease in patients who died from COVID-19. 20 24, 25 30 
However, these have been mostly limited by their small sample size or analysis of selected 
cohorts (e.g. intensive care admission only). In our analysis we find that a third of individuals 
who died had no underlying chronic conditions, but there were more chronic conditions in 
COVID than non-COVID deaths, with the most prevalent reported being hypertension, 
dementia, chronic lung disease and diabetes in both groups. 
Interestingly, we find that the prevalence of ischemic heart disease in COVID-19 
related deaths is similar to that observed in non COVID-19 deaths, apart from in younger 
men (<60 years old) where paradoxically the prevalence is double that in patients that died 
non-COVID deaths. Reports from several studies have demonstrated a high prevalence of 
cardiovascular disease (CVD) in patients with COVID-19. 25 24 31 Although the underlying 
mechanisms are unclear, patients with CVD are more likely to develop severe COVID-
infection, which is attributed to multiple factors including advanced age, lower ACE2 levels 
and impaired immunity. 32 It is also possible that pharmacological treatment administered for 
COVID infection provokes fatal arrhythmias, to which CVD patients appear to be more 
Page 11 of 87































































susceptible. 33 In a meta-analysis of 1576 COVID-infected patients, the most prevalent 
comorbidities were hypertension (21.1%), diabetes (9.7%) and CVD (8.4%). Their analysis 
showed that the odds ratios (OR) of hypertension and CVD were significantly higher in 
patients with severe than non-severe COVID (OR 2.36 (95% confidence interval (CI): 1.46–
3.83) and 3.42 (95% CI: 1.88–6.22), respectively). 34 However, these data may not hold true 
in patients who die from COVID, who may have greater baseline comorbidity. In a report 
from the Italian Instituto Superiore Di Sanita the prevalence of hypertension (68.3%) and 
ischemic heart disease (28.3%) was significantly higher in COVID deaths (n=31.096). 35 
Differences between countries may reflect differences in reporting methods, or 
sociodemographic and genetic differences. 
Amongst COVID deaths, acute conditions were observed to be either similar between 
sexes (pulmonary embolism) or more prevalent in men (ACS and acute stroke).  In terms of 
chronic conditions, women had higher rates of dementia, heart failure and chronic lung 
disease compared to men, whilst men had higher rates of pre-existing IHD, CKD, 
hypertension and diabetes. Notably, there was no difference in the rates of underlying cancer 
between sexes. Although the pattern of findings was consistent across age groups, certain 
differences in underlying conditions were noted. Pulmonary embolism was more frequently 
reported in <60 and 60-69 age deciles amongst COVID deaths, more so in men than women, 
whereas cancer rates were higher in younger age groups, especially in women compared to 
men. Data on 31.096 COVID deaths from Italy shows that men had a higher prevalence of 
IHD (31.7% vs. 21.3%), diabetes (30.8% vs. 28.8%) and chronic renal failure (21.5% vs. 
18.2%) and lower prevalence of heart failure (14.6% vs. 18.1%), compared to women, and 
that there was no difference in the rates of active cancer between sexes (men: 15.9% vs. 
women: 15.6%), all of which are in line with our findings. 35 However, their report did not 
compare these conditions between age groups. 
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The present findings have several important implications from a national and 
international perspective. Our comprehensive analysis adds to the body of literature on sex 
and age differences in patterns of death from a national perspective in a population with a 
high mortality rank. Furthermore, our report of underlying medical conditions in the overall 
population of COVID-19 deaths, as well as in both sexes, may help inform stakeholders’ and 
governments’ policies by identifying high-risk groups who could benefit from prolonged 
shielding, especially in the event of a second peak, and/or vaccination priority in the future. 
Limitations
 Although our study provides insights into the patterns of age and sex differences in 
COVID-19-related deaths and reported underlying medical conditions in a full nationwide 
cohort from England and Wales, there are a number of limitations. First, only conditions that 
were thought to contribute to the death are entered on the death certificate, rather than a list 
of all comorbid conditions that a patient may have. Our analysis therefore provides an 
overview of comorbid conditions that were judged by clinicians completing the death 
certificate to have contributed to death, without any external auditing, rather than a 
description of all prevalent comorbid conditions. Second, we did not have access to ethnic 
data, that may confound our analyses, particularly given that the mortality rate from COVID-
19 in Black, Asian and minority ethnic people have been reported as up to three times 
greater.36 
Conclusions
In this nationwide analysis of deaths in England and Wales between 1st March and 
12th May 2020, we demonstrate that the age-adjusted mortality of COVID-19 was higher than 
that of other primary causes of death across all age groups and in both sexes, with the 
exception of cancer mortality in women between 30-79 years, whose adjusted-mortality was 
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higher than COVID-19. Our findings also suggest persistently higher age-adjusted mortality 
in men compared to women across all age groups throughout the study period. Our report of 
underlying medical conditions in the overall population of COVID-19 deaths, as well as in 
both sexes, may help inform stakeholders’ and government body policies by identifying high-
risk groups. 
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Figures captions and legends:
Figure 1. Distribution of Covid-19 deaths in England and Wales from the start of the pandemic 
through 12th May 2020 according to sex
Figure 2. Age standardized mortality rate according to COVID status (per 100,000 population)
Figure 3. Number of reported underlying chronic conditions in the overall cohort and according to 
COVID status and sex
Figure 4. Top reported conditions associated with COVID and non-COVID deaths in England and 
Wales in overall cohort and according to sex and age group
Legend: ACS: acute coronary syndrome; CKD: chronic kidney disease: IHD: ischaemic heart 
disease; PE: pulmonary embolism
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18-29 126 0.2% 2.7 85 0.2% 1.9 211 0.2% 2.3 37 0.2% 0.8 25 0.2% 0.6 62 0.2% 0.7
30-39 297 0.6% 7.6 261 0.5% 6.6 558 0.5% 7.1 103 0.5% 2.6 72 0.5% 1.8 175 0.5% 2.2
40-49 965 1.9% 25.7 774 1.4% 20.3 1739 1.6% 23 342 1.7% 9.1 195 1.2% 5.1 537 1.5% 7.1
50-59 3005 5.8% 76.9 2158 3.9% 53.7 5163 4.8% 65.2 1204 5.8% 30.8 621 3.9% 15.5 1825 5.0% 23
60-69 6321 12.2% 207.8 4446 7.9% 139.0 10767 10.0% 172.5 2555 12.3% 84 1275 8.1% 39.9 3830 10.5% 61.4
70-79 13298 25.6% 576.1 10326 18.4% 400.7 23624 21.9% 483.6 5427 26.2% 235.1 3127 19.9% 121.3 8554 23.5% 175.1
80-89 18867 36.4% 1853.9 20233 36.1% 1452.9 39100 36.3% 1622.2 7942 38.4% 780.4 6247 39.7% 448.6 14189 38.9% 588.7
90+ 9000 17.3% 5388.9 17696 31.6% 4889.3 26696 24.8% 5047.1 3097 15.0% 1854.4 4169 26.5% 1151.8 7266 19.9% 1373.6
a ASMR: per 100,000 population
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Table 2. Frequencies and age-standardised mortality rates (ASMR) of primary causes of deaths
Age group (years)
Primary cause of 
death, n (ASMRa)
18-29 30-39 40-49 50-59 60-69 70-79 80-89 90+
COVID-19
Men 37 (0.8) 103 (2.6) 342 (9.1) 1204 (30.8) 2555 (84) 5427 (235.1) 7942 (780.4) 3097 (1854.4)
Women 25 (0.6) 72 (1.8) 195 (5.1) 621 (15.5) 1275 (39.9) 3127 (121.3) 6247 (448.6) 4169 (1151.8)
Total 62 (0.7) 175 (2.2) 537 (7.1) 1825 (23) 3830 (61.4) 8554 (175.1) 14189 (588.7) 7266 (1373.6)
AKI
Men 1 (0) 0 (0) 1 (0) 8 (0.2) 23 (0.8) 63 (2.7) 108 (10.6) 36 (21.6)
Women 0 (0) 0 (0) 1 (0) 10 (0.2) 30 (0.9) 47 (1.8) 101 (7.3) 54 (14.9)
Total 1 (0) 0 (0) 2 (0) 18 (0.2) 53 (0.8) 110 (2.3) 209 (8.7) 90 (17)
PE
Men 1 (0) 17 (0.4) 23 (0.6) 73 (1.9) 135 (4.4) 149 (6.5) 98 (9.6) 20 (12)
Women 5 (0.1) 15 (0.4) 22 (0.6) 38 (0.9) 89 (2.8) 153 (5.9) 160 (11.5) 59 (16.3)
Total 6 (0.1) 32 (0.4) 45 (0.6) 111 (1.4) 224 (3.6) 302 (6.2) 258 (10.7) 79 (14.9)
Stroke
Men 6 (0.1) 10 (0.3) 42 (1.1) 103 (2.6) 198 (6.5) 388 (16.8) 514 (50.5) 201 (120.4)
Women 1 (0) 9 (0.2) 38 (1) 81 (2) 166 (5.2) 454 (17.6) 849 (61) 594 (164.1)
Total 7 (0.1) 19 (0.2) 80 (1.1) 184 (2.3) 364 (5.8) 842 (17.2) 1363 (56.6) 795 (150.3)
ACS
Men 0 (0) 10 (0.3) 66 (1.8) 187 (4.8) 348 (11.4) 532 (23) 486 (47.8) 127 (76)
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Women 2 (0) 4 (0.1) 14 (0.4) 36 (0.9) 102 (3.2) 254 (9.9) 356 (25.6) 197 (54.4)
Total 2 (0) 14 (0.2) 80 (1.1) 223 (2.8) 450 (7.2) 786 (16.1) 842 (34.9) 324 (61.3)
Acute respiratory 
failure
Men 2 (0) 5 (0.1) 8 (0.2) 41 (1) 78 (2.6) 152 (6.6) 124 (12.2) 33 (19.8)
Women 3 (0.1) 5 (0.1) 11 (0.3) 31 (0.8) 74 (2.3) 162 (6.3) 141 (10.1) 47 (13)
Total 5 (0.1) 10 (0.1) 19 (0.3) 72 (0.9) 152 (2.4) 314 (6.4) 265 (11) 80 (15.1)
Respiratory infections
Men 23 (0.5) 24 (0.6) 82 (2.2) 258 (6.6) 733 (24.1) 2181 (94.5) 3841 (377.4) 2035 (1218.5)
Women 7 (0.2) 24 (0.6) 61 (1.6) 209 (5.2) 539 (16.8) 1523 (59.1) 3508 (251.9) 3054 (843.8)
Total 30 (0.3) 48 (0.6) 143 (1.9) 467 (5.9) 1272 (20.4) 3704 (75.8) 7349 (304.9) 5089 (962.1)
Other infections
Men 7 (0.2) 9 (0.2) 26 (0.7) 77 (2) 170 (5.6) 491 (21.3) 814 (80) 346 (207.2)
Women 5 (0.1) 11 (0.3) 26 (0.7) 61 (1.5) 145 (4.5) 381 (14.8) 829 (59.5) 584 (161.3)
Total 12 (0.1) 20 (0.3) 52 (0.7) 138 (1.7) 315 (5) 872 (17.8) 1643 (68.2) 930 (175.8)
Chronic lung disease
Men 0 (0) 0 (0) 8 (0.2) 41 (1) 151 (5) 373 (16.2) 284 (27.9) 67 (40.1)
Women 0 (0) 0 (0) 6 (0.2) 38 (0.9) 139 (4.3) 346 (13.4) 283 (20.3) 92 (25.4)
Total 0 (0) 0 (0) 14 (0.2) 79 (1) 290 (4.6) 719 (14.7) 567 (23.5) 159 (30.1)
Old age (senility)
Men 0 (0) 0 (0) 0 (0) 0 (0) 1 (0) 27 (1.2) 906 (89) 1224 (732.9)
Women 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 36 (1.4) 1440 (103.4) 3288 (908.4)
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Total 0 (0) 0 (0) 0 (0) 0 (0) 1 (0) 63 (1.3) 2346 (97.3) 4512 (853)
Dementia
Men 0 (0) 0 (0) 0 (0) 7 (0.2) 70 (2.3) 543 (23.5) 1589 (156.1) 710 (425.1)
Women 0 (0) 0 (0) 1 (0) 17 (0.4) 94 (2.9) 710 (27.6) 2736 (196.5) 2383 (658.4)
Total 0 (0) 0 (0) 1 (0) 24 (0.3) 164 (2.6) 1253 (25.6) 4325 (179.4) 3093 (584.7)
Heart Failure
Men 2 (0) 8 (0.2) 38 (1) 119 (3) 285 (9.4) 646 (28) 1023 (100.5) 471 (282)
Women 1 (0) 4 (0.1) 17 (0.4) 43 (1.1) 98 (3.1) 408 (15.8) 884 (63.5) 628 (173.5)
Total 3 (0) 12 (0.2) 55 (0.7) 162 (2) 383 (6.1) 1054 (21.6) 1907 (79.1) 1099 (207.8)
CKD
Men 0 (0) 0 (0) 2 (0.1) 18 (0.5) 38 (1.2) 72 (3.1) 128 (12.6) 46 (27.5)
Women 1 (0) 1 (0) 0 (0) 6 (0.1) 25 (0.8) 45 (1.7) 104 (7.5) 22 (6.1)
Total 1 (0) 1 (0) 2 (0) 24 (0.3) 63 (1) 117 (2.4) 232 (9.6) 68 (12.9)
Cancers
Men 11 (0.2) 82 (2.1) 254 (6.8) 962 (24.6) 2086 (68.6) 3724 (161.3) 3393 (333.4) 862 (516.1)
Women 14 (0.3) 103 (2.6) 321 (8.4) 970 (24.2) 1815 (56.7) 3175 (123.2) 3011 (216.2) 906 (250.3)
Total 25 (0.3) 185 (2.3) 575 (7.6) 1932 (24.4) 3901 (62.5) 6899 (141.2) 6404 (265.7) 1768 (334.2)
Other causes
Men 73 (1.6) 132 (3.4) 415 (11.1) 1111 (28.4) 2005 (65.9) 3957 (171.4) 5559 (546.2) 2822 (1689.7)
Women 46 (1) 85 (2.1) 256 (6.7) 618 (15.4) 1130 (35.3) 2632 (102.1) 5831 (418.7) 5788 (1599.1)
Total 119 (1.3) 217 (2.8) 671 (8.9) 1729 (21.8) 3135 (50.2) 6589 (134.9) 11390 (472.6) 8610 (1627.7)
a ASMR: per 100,000 population
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Age, median (IQR) 81 (72, 87) 85 (76, 91) 83 (74, 89) <.001 80 (72, 87) 84 (76, 90) 82 (73, 88) <.001
Month of death, n (row 
%) <.001 <.001
March 23564 (49.9) 23649 (50.1) 47213 2804 (61.7) 1739 (38.3) 4543
April 23591 (46.9) 26687 (53.1) 50278 16221 (56.8) 12335 (43.2) 28556
Maya 4724 (45.6) 5644 (54.4) 10368 1682 (50.4) 1657 (49.6) 3339




0 14821 (28.6) 17388 (31.1) 32209 (29.9) 6318 (30.5) 5287 (33.6) 11605 (31.8)
1 21904 (42.2) 25225 (45.1) 47129 (43.7) 7501 (36.2) 6028 (38.3) 13529 (37.1)
2 9729 (18.8) 9071 (16.2) 18800 (17.4) 4537 (21.9) 2965 (18.8) 7502 (20.6)
≥3 5425 (10.5) 4296 (7.7) 9721 (9) 2351 (11.4) 1451 (9.2) 3802 (10.4)
Chronic conditions
Pre-existing Ischaemic 
Heart Disease, n (%) 8114 (15.6) 4799 (8.6) 12913 (12) <.001 2918 (14.1) 1235 (7.9) 4153 (11.4) <.001
Heart Failure, n (%) 5907 (11.4) 5312 (9.5) 11219 (10.4) <.001 1609 (7.8) 1301 (8.3) 2910 (8) .08
Dementia, n (%) 6620 (12.8) 10490 (18.7) 17110 (15.9) <.001 3523 (17) 3328 (21.2) 6851 (18.8) <.001
Chronic Kidney 
Disease, n (%) 4173 (8) 4099 (7.3) 8272 (7.7) <.001 2354 (11.4) 1500 (9.5) 3854 (10.6) <.001
Hypertension, n (%) 5655 (10.9) 6407 (11.4) 12062 (11.2) .005 4171 (20.1) 2740 (17.4) 6911 (19.0) <.001
Chronic Lung Disease, 
n (%) 6550 (12.6) 5755 (10.3) 12305 (11.4) <.001 3125 (15.1) 2559 (16.3) 5684 (15.6) .002
Diabetes, n (%) 4833 (9.3) 3937 (7) 8770 (8.1) <.001 3531 (17.1) 2020 (12.8) 5551 (15.2) <.001
Liver Disease, n (%) 1516 (2.9) 895 (1.6) 2411 (2.2) <.001 278 (1.3) 182 (1.2) 460 (1.3) .12
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Disease, n (%) 1189 (2.3) 854 (1.5) 2043 (1.9) <.001 357 (1.7) 130 (0.8) 487 (1.3) <.001
Valvular Heart Disease, 
n (%) 1019 (2) 881 (1.6) 1900 (1.8) <.001 273 (1.3) 202 (1.3) 475 (1.3) .78
Cancers, n (%) 12475 (24) 12745 (22.8) 25220 (23.4) <.001 1615 (7.8) 1216 (7.7) 2831 (7.8) .81
Acute conditions
Strokeb, n (%) 3620 (7) 4309 (7.7) 7929 (7.4) <.001 1287 (6.2) 839 (5.3) 2126 (5.8) <.001
Major Bleeding, n (%) 1585 (3.1) 1575 (2.8) 3160 (2.9) .02 218 (1.1) 120 (0.8) 338 (0.9) .004
Pulmonary embolism, n 
(%) 932 (1.8) 1027 (1.8) 1959 (1.8) .64 280 (1.4) 181 (1.2) 461 (1.3) .09
Acute Coronary 
Syndrome, n (%) 2614 (5) 1529 (2.7) 4143 (3.8) <.001 307 (1.5) 137 (0.9) 444 (1.2) <.001
Infective Endocarditis, 
n (%) 390 (0.8) 343 (0.6) 733 (0.7) .005 85 (0.4) 80 (0.5) 165 (0.5) .17
a Correct as of 12th May 2020
b Includes bleeding and ischaemic strokes
IQR: interquartile range
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Sex-based Differences in Reported Underlying Conditions and Rates of COVID-19 
Deaths in England and Wales 
 
Online Supplementary Material  
 
- Table S1. List of ICD-10 CM diagnosis codes used in the study 
- Table S2. Rates of COVID-19 deaths per county region according to sex 
- Table S3. Characteristics and reported underlying conditions of deceased patients A) 
without and B) with COVID -19 according to sex and age group 
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Table S1. List of ICD-10 CM* diagnosis codes used in the study 
Diagnosis Codes 
COVID-19 U07.1 
Pre-existing Ischaemic Heart 
Disease 
I25.2, I25.6, Z98.61, I25.10, I25.110, I25.111, 
I25.118, I25.119, I25.7*, I25.8*, I25.9*, Z95.1 
Heart Failure I50*, I42*, I25.5 
Dementia F01*, F02*, F03* 
Chronic Kidney Disease N18* 
Hypertension I10* 
Chronic Lung Disease J41*, J42*, J43*, J44*, J45*, J47* 
Diabetes E08*, E09*, E10*, E11*, E13* 
Liver Disease K70*, K72.1*, K72.9*, K73*, K74*, K75*, K76*, K77* 
Peripheral Vascular Disease I70*, I73* 
Valvular Heart Disease I34*, I35*, I36*, I37* 
Cancers C00-C96* 
Stroke G46.3, G46.4, G46.5, G46.6, G46.7, I60*, I61*, I62*, I63*, I64* 
Major Bleeding 
I60*, I61*, I62*, R58, K92.0, K92.1, K92.2, K25.0, 
K25.1, K25.2, K25.4, K25.5, K25.6, K26.0, K26.1, 
K26.2, K26.4, K26.5, K266, K27.0, K27.1, K27.2, 
K27.4, K27.5, K27.6, K28.0, K28.1, K28.2, K28.4, 
K28.5, K28.6 
Pulmonary embolism I26* 
Acute Coronary Syndrome I20*, I21*, I22* 
Infective Endocarditis I33*, I38*, I39* 
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Table S2. Rates of COVID-19 deaths per county region according to sex 
County Men Women Total 
Bedfordshire 267 (1.3%) 168 (1.1%) 435 (1.2%) 
Berkshire 298 (1.4%) 271 (1.7%) 569 (1.6%) 
Bristol 152 (0.7%) 114 (0.7%) 266 (0.7%) 
Buckinghamshire 204 (1%) 190 (1.2%) 394 (1.1%) 
Cambridgeshire 201 (1%) 141 (0.9%) 342 (0.9%) 
Cheshire 422 (2.1%) 341 (2.2%) 763 (2.1%) 
Cornwall 91 (0.4%) 46 (0.3%) 137 (0.4%) 
Cumbria 191 (0.9%) 165 (1.1%) 356 (1%) 
Derbyshire 337 (1.6%) 270 (1.7%) 607 (1.7%) 
Devon 166 (0.8%) 128 (0.8%) 294 (0.8%) 
Dorset 54 (0.3%) 39 (0.2%) 93 (0.3%) 
Durham 317 (1.5%) 302 (1.9%) 619 (1.7%) 
East Sussex 161 (0.8%) 127 (0.8%) 288 (0.8%) 
East York 146 (0.7%) 78 (0.5%) 224 (0.6%) 
Essex 745 (3.6%) 505 (3.2%) 1250 (3.5%) 
Gloucestershire 269 (1.3%) 235 (1.5%) 504 (1.4%) 
Hampshire 493 (2.4%) 364 (2.3%) 857 (2.4%) 
Hertfordshire 452 (2.2%) 364 (2.3%) 816 (2.3%) 
Isle of Wight 21 (0.1%) 22 (0.1%) 43 (0.1%) 
Kent 535 (2.6%) 407 (2.6%) 942 (2.6%) 
Lancashire 275 (1.3%) 182 (1.2%) 457 (1.3%) 
Lancashire 174 (0.8%) 139 (0.9%) 313 (0.9%) 
Leicestershire 257 (1.3%) 211 (1.4%) 468 (1.3%) 
Lincolnshire 154 (0.7%) 113 (0.7%) 267 (0.7%) 
London 4519 (22%) 2991 (19.1%) 7510 (20.8%) 
Manchester 1256 (6.1%) 1023 (6.5%) 2279 (6.3%) 
Merseyside 752 (3.7%) 578 (3.7%) 1330 (3.7%) 
Norfolk 235 (1.1%) 149 (1%) 384 (1.1%) 
North Yorkshire 370 (1.8%) 297 (1.9%) 667 (1.8%) 
Northampton 216 (1.1%) 176 (1.1%) 392 (1.1%) 
Northumberland 118 (0.6%) 97 (0.6%) 215 (0.6%) 
Nottinghamshire 367 (1.8%) 311 (2%) 678 (1.9%) 
Oxfordshire 221 (1.1%) 183 (1.2%) 404 (1.1%) 
Rutland <15 (0%)* <15 (0%)* <15 (0%)* 
Shropshire 117 (0.6%) 95 (0.6%) 212 (0.6%) 
Somerset 102 (0.5%) 62 (0.4%) 164 (0.5%) 
South Yorkshire 460 (2.2%) 430 (2.8%) 890 (2.5%) 
Stafford 336 (1.6%) 276 (1.8%) 612 (1.7%) 
Suffolk 184 (0.9%) 140 (0.9%) 324 (0.9%) 
Surrey 547 (2.7%) 436 (2.8%) 983 (2.7%) 
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Tyne & Wear 432 (2.1%) 426 (2.7%) 858 (2.4%) 
Wales 810 (3.9%) 638 (4.1%) 1448 (4%) 
Warwick 213 (1%) 161 (1%) 374 (1%) 
West Midlands 1543 (7.5%) 1113 (7.1%) 2656 (7.3%) 
West Sussex 176 (0.9%) 144 (0.9%) 320 (0.9%) 
West Yorkshire 795 (3.9%) 614 (3.9%) 1409 (3.9%) 
Wiltshire 194 (0.9%) 168 (1.1%) 362 (1%) 
Worcestershire 211 (1%) 196 (1.3%) 407 (1.1%) 
*Exact number not revealed for confidentiality purposes 
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Men Women Total Men Women Total Men Women Total Men Women Total Men Women Total 
Number of reported 
chronic underlying 
conditions 
               
















































































































Chronic conditions                
Pre-existing Ischaemic 
Heart Disease, n (%) 
456 




















































































Disease, n (%) 
146 
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Disease, n (%) 
59 
(1.3) 21 (0.6) 80 (1) 
164 






















Disease, n (%) 
39 




















(1.6) 531 (2) 





























Acute conditions                



























































































Syndrome, n (%) 
372 
























(1.7) 532 (2) 
Infective 


















(0.5) 80 (0.5) 
126 
(0.5) 
n=number of cases 
a Includes bleeding and ischaemic strokes 
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Men Women Total Men Women Total Men Women Total Men Women Total Men Women Total 
Number of reported 
chronic underlying 
conditions 
               













































































































(9.6) 292 (7) 
589 
(8.1) 
Chronic conditions                
Pre-existing Ischaemic 
Heart Disease, n (%) 
88 
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(0.5) 30 (0.5) 
70 
(0.5) 5 (0.2) 3 (0.1) 8 (0.1) 
Peripheral Vascular 
Disease, n (%) 
13 




















Disease, n (%) 4 (0.2) 4 (0.4) 8 (0.3) 
17 














(1.9) 55 (1.3) 
113 
(1.6) 
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(0.7) 30 (1) 
69 




























Syndrome, n (%) 
26 












(1.4) 57 (0.9) 
169 




n (%) 6 (0.4) 5 (0.5) 
11 








(0.5) 38 (0.6) 
76 
(0.5) 9 (0.3) 14 (0.3) 
23 
(0.3) 
n=number of cases 
a Includes bleeding and ischaemic strokes 
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Abbreviations
ACS Acute coronary syndrome
ASMR Age standardized mortality rate
CVD Cardiovascular disease
IHD Ischemic heart disease
ONS Office for National Statistics
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Abstract
Background: Limited national data exists on the prevalence and distribution of underlying 
conditions among COVID-19 deaths between sexes and across age groups. 
Methods: All adult (≥18 years) deaths recorded in England and Wales (1st March 2020 to 
12th May 2020) were retrospectively analyzed. We compared 1) the prevalence of underlying 
health conditions between COVID and non-COVID related deaths during the COVID-19 
pandemic and 2) the age-standardized mortality rate (ASMR) of COVID-19 compared with 
other primary causes of death, stratified by sex and age group.
Results: Of 144,279 adult deaths recorded during the study period, 36,438 (25.3%) were 
confirmed COVID cases. Women represented 43.2% (n=15,731) of COVID deaths compared 
to 51.9% (n=55,980) in non-COVID deaths. Overall, COVID deaths were younger non-
COVID deaths (82 vs. 83 years). ASMR of COVID-19 was higher than all other common 
primary causes of death, across age groups and sexes, except for cancers in women between 
the ages of 30-79 years. A linear relationship was observed between ASMR and age amongst 
COVID-19 deaths, with persistently higher rates in men than women across all age groups. 
The most prevalent reported conditions were hypertension, dementia, chronic lung disease 
and diabetes, and these were higher amongst COVID deaths. Pre-existing ischemic heart 
disease was similar in COVID (11.4%) and non-COVID (12%) deaths. 
Conclusions: In a nationwide analysis, COVID-19 infection was associated with higher age-
standardized mortality than other primary causes of death, except cancer in women of select 
age groups. COVID-19 mortality was persistently higher in men and increased with advanced 
age. 
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Introduction
More than 12 million patients worldwide have been infected with the severe acute 
respiratory syndrome coronavirus (SARS-CoV-2), resulting in the illness referred to as 
COVID-19.1 The United Kingdom (UK) has the second highest recorded number of deaths in 
the world after the US, with 39,728 deaths recorded as of 6th June 2020. 2 3
Age and comorbidities such as hypertension,  diabetes and ischemic heart disease 
(IHD) are strong predictors of adverse outcomes and mortality in people infected with 
COVID-19. 4 5 6 Furthermore, differences in COVID-19 survival has been observed between 
sexes, with females shown to have better outcomes. Several hypotheses have been proposed 
as an explanation of the latter, including biological (genetic and hormonal) differences 
between sexes as well as lower burden of comorbidity in females.4-8 Detailed data concerning 
underlying conditions is limited, with data from New York state reporting that 89.7% of 
fatalities attributed to COVID-19 had at least one comorbidity, most commonly hypertension, 
diabetes and hyperlipidemia.9 In the UK 91% of COVID-19 deaths in March 2020 had at 
least one pre-existing condition, with ischemic heart disease the most common (14%).10 
There is inconclusive evidence, however, on how the distribution of underlying conditions 
varies by sex and age in those that have died from COVID-19. 11-13 Furthermore, it is unclear 
as to how the underlying conditions in COVID-19 deaths differ from those in similar age/sex 
groups that have died from non-COVID related causes. 
Therefore, we investigated the pre-existing conditions in adults (≥18 years) who had 
died from COVID-19 in England and Wales between 1st March 2020 and 12th May 2020, 
stratified by sex and age group, and compare this with patients whose death was not 
attributed to COVID-19. 
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Methods
Data Source, Study Design and Population
This cross-sectional study included records of all adult (aged ≥18 years) deaths 
between 1st March 2020 and 12th May 2020 in England and Wales were collected from the 
Office for National Statistics (ONS) Civil Registrations of Death dataset and stratified 
according to COVID-19 status. 2 Children and adolescents aged below 18 years were 
excluded for the purpose of this analysis since their susceptibility to death from COVID-19 is 
significantly lower than adults, and the pattern of their causes of death vary to those in adults. 
14 The process of death certification and registration is a legal requirement in the United 
Kingdom where a doctor who has seen the deceased within the last 14 days of life must 
complete a Medical Cause of Death Certificate unless a post-mortem examination is planned. 
During the COVID-19 pandemic, the 14-day requirement was temporarily extended to 28 
days allowing for the exceptional circumstances. The ONS dataset includes information 
concerning the deceased’s age, sex, registration office (town or city), primary cause of death 
as well as up to 15 supplementary codes for their underlying conditions. A total of 900 
patients younger than 18 years of age were excluded. There were no other inclusion or 
exclusion criteria. The International Classification of Diseases, tenth revision (ICD-10) codes 
were used to extract data on COVID-19 (as the primary cause of death), pulmonary 
embolism, pre-existing IHD, heart failure, dementia, chronic kidney disease (CKD), 
hypertension, chronic lung disease, diabetes, liver, peripheral vascular disease (PVD), 
valvular heart disease, major bleeding, cancers, stroke (ischemic and hemorrhagic), acute 
coronary syndrome (ACS) and infective endocarditis. A full list of diagnosis codes used in 
the study is provided in Supplementary Table S1.
Page 51 of 87
































































Underlying Conditions in COVID-19 Deaths
© 2020 Mayo Foundation for Medical Education and Research. Mayo Clin Proc. 2020;95(x):xx-xx.       6
Statistical Analysis
We compared the reported underlying acute and chronic conditions between patients 
with and without confirmed COVID-19 as the underlying primary contributory cause, 
stratified according to sex, and age band (18-29, 30-39, 40-49, 50-59, 60-69, 70-79, 80-89 
and ≥90 years). Age was not normally distributed and therefore summarized using median 
and interquartile range (IQR) and compared using the Kruskal-Wallis test. Categorical 
variables were summarized as percentages and analyzed using the chi squared (X2) test or 
Fisher’s exact test, where appropriate. Age-standardized mortality rates (ASMR), expressed 
as rates per 100,000 capita, were calculated for each age band based on the mid-2019 
population census for England and Wales. 15Statistical analyses were performed using Stata 
16 MP (College Station, TX).
Ethical Approval
This work was endorsed by the Scientific Advisory Group for Emergencies (SAGE), 
the body responsible for ensuring timely and coordinated scientific advice is made available 
to UK government decision makers. SAGE supports UK cross-government decisions in the 
Cabinet Office Briefing Room (COBR)) and by NHS England, which overseas 
commissioning decisions in the NHS, and NHS Improvement, which is responsible for 
overseeing quality of care in NHS hospitals.
Results
A total of 36,438 adult COVID-19 deaths were recorded in England and Wales 
between 1st March and 12th May 2020, of which 20,707 (56.8%) were in men and 15,731 
(43.2%) in women. The first death due to COVID-19 infection in the United Kingdom was 
recorded on 2nd March 2020. Over the same period a total of 107,859 non-COVID related 
deaths were recorded, including 51,879 (48.1%) in men and 55,980 (51.9%) in women. The 
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median age of COVID-19 deaths was lower than that in non-COVID related deaths (82 
(73,88) vs. 83 (74, 89) years). Overall, women were older in the COVID and non-COVID 
groups (84 (76, 90) vs. 80 (72, 87) years, p<0.001). 
The majority of death were observed among people aged 80-89 years (COVID: 
38.9%, non-COVID: 36.4%, Table 1). ASMR increased with age in both groups and were 
consistently higher for all age bands for non-COVID compared with COVID deaths. The 
ASMR was 61.4 per 100,000 population in the 60-69 age group for COVID deaths and 172.5 
per 100,000 population for non-COVID deaths. The absolute number of COVID-19 deaths 
was higher for men than women throughout the study period (Figure 1), with peak mortality 
observed between the 4th and 20th April 2020. The ASMR was approximately two-fold higher 
in men compared to women across all age groups for COVID-19 related deaths. (Table 1, 
Figure 2) A similar pattern was observed in the non-COVID group, albeit with less 
pronounced sex differences in ASMR.  Overall, the most common cause of death in younger 
age groups (<60 years) was cancer, whereas the most common causes of death in older age 
groups (>80 years) were dementia, cancer and old age (Table 2). However, ASMR of 
COVID-19 was higher than all other primary causes of death for people without COVID-19 
across all age groups and sexes, with the exception of cancer deaths for women aged 30-79 
years. The highest number of COVID-19 deaths was in London (total/male/female: 7,510, 
4,519, 2,991). (Table S2, Figure S1)
Approximately a third of individuals had no underlying chronic conditions in the non-
COVID (29.9%) and COVID groups (31.8%), and close to one in ten patients with COVID-
19 and non-COVID-19 deaths had three or more underlying conditions (10.4% vs. 9%). 
(Table 3, Figure 3) The rate of reported underlying chronic conditions was generally higher 
in COVID than non-COVID deaths, with the most prevalent reported conditions being 
hypertension (COVID vs. non-COVID: 19.0% and 11.2%), dementia (COVID vs. non-
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COVID: 18.8% vs. 15.9%), chronic lung disease (COVID vs. non-COVID: 15.6% vs. 11.4%) 
and diabetes (COVID vs. non-COVID: 15.2% vs. 8.1%). The rates of pre-existing IHD were 
similar in COVID (11.4%) and non-COVID (12%) deaths, although lower reported rates of 
cancers (7.8% vs. 23.4%) were observed amongst patients with reported COVID deaths. 
(Table 3) The prevalence of pre-existing IHD appeared to be significantly lower in men in 
the COVID-19 vs the non COVID-19 deaths among those aged <60 years but was similar for 
all other age groups. (Supplementary Tables S3A and S3B)
 Overall, women were more likely to have no underlying chronic conditions compared 
with men in both COVID and non-COVID groups (COVID: 33.6% vs. 30.5%, non-COVID: 
31.1% vs. 28.6%, Table 3, Figures 3 and 4). Amongst COVID-19 deaths, women had higher 
rates of dementia (21.2% vs. 17%, p<.001) as underlying conditions compared with men 
whilst men had higher rates of pre-existing IHD (14.1% vs. 7.9%), CKD (11.4% vs. 9.5%), 
hypertension (20.1% vs. 17.4%), diabetes (17.1% vs. 12.8%) compared with women (p<.001 
for all). There was no difference in the rates of underlying cancer, liver disease, pulmonary 
embolism and valvular heart disease between sexes. While this pattern was generally 
consistent across the age groups, the rates of certain underlying conditions were higher for 
the younger age bands (Table S3A and S3B, Figure 4) Pulmonary embolism was more 
frequently reported in <60 and 60-69 age deciles, more so in men than women (<60 years: 
3.0% vs. 2.6%, 60-69 years: 2.9% vs. 1.8%, p<.001 for both). Individuals in the younger age 
deciles were also more likely to have cancer with higher rates observed in women compared 
to men (<60 years: 12.5% vs. 7.4%, 60-69 years: 14% vs. 10%, p<.001 for both). 
Discussion
This national study is the first to report detailed, patient-level data about the 
prevalence of underlying conditions according to COVID-19 status in England & Wales 
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during the COVID-19 pandemic. We found that the age-standardized mortality rate for 
COVID-19 was higher than that from all common primary causes of death in non-COVID 
patients, across all age groups and sexes, except for cancers in women between the ages of 
30-79 years. Second, we show that age standardized mortality was consistently higher for 
men than women for COVID-19 deaths by a factor of almost 2 across age groups. Finally, we 
provide a contrast of the distribution of underlying acute and chronic conditions between 
COVID and non-COVID related deaths, and report that hypertension, chronic lung diseases 
and diabetes were more commonly observed in COVID-19 deaths whereas cancers where 
more commonly observed in non-COVID deaths.
The greatest proportion of COVID deaths in England and Wales were observed in the 
70-79 and 80-89 age groups, with the median age being 82 years. The median age of death in 
Italy was 81 years, based on 31,096 deaths (as of May 21st, 2020), which is similar to our 
findings. Their report demonstrates that the highest number of deaths was observed in the 80-
89 years group (n=12,729/31, 096), followed by 70-79 years (n=8466) and ≥90 years 
(n=5227), however age standardized mortality rates were not presented which makes 
interpretation of data difficult, particularly when comparing with non-COVID deaths, or data 
derived from other countries. 16 Similarly, data from the National Center for Health Statistics 
(NCHS) as of 13th May 2020 demonstrates that mortality was highest in the 75-84 and ≥85-
year groups (27.2% and 31.8%, respectively) in the United States but, again they do not 
present age-adjusted figures.17 
The majority of recent studies have focused on the crude mortality or case-fatality 
rates of COVID-19. 18-21 The latter is a proportion of the cumulative reported number of 
deaths by the cumulative number of reported cases and can be misleading since there is often 
a lag in the manifestation of symptoms, testing for disease and reporting of the number of 
cases, meaning that the true case fatality rate is often underestimated as demonstrated with 
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previous epidemics. 22, 23 Age-standardized mortality rates take in to account differences in 
the age structure of a population and allow a more direct comparison of underlying 
conditions especially when these vary by age. Whilst there have been several reports about 
mortality during the COVID-19 pandemic, these have either not been derived from national 
populations or have not compared mortality rates with other causes of death within the 
population. 17, 19, 24-27 Our analysis, which provides full population coverage of all deaths in 
England and Wales, is the first to demonstrate that the age standardized mortality rate of 
COVID is significantly higher than that of any other primary cause of death in non-COVID 
subjects throughout the same period. This finding was consistent across all age groups and in 
both sexes, with the exception of women between 30-79 years whose mortality from cancer 
was comparable to that from COVID. 
Our findings suggest that age-standardized mortality in men was almost double 
compared to that of women across all age groups, despite crude death rates suggesting a 
significantly higher proportion of women ≥90 years dying from COVID-19 compared with 
men. Our crude findings are consistent with reports in the US, which show 41.7% of female 
deaths were amongst those 85 years and older compared to only 23.9% in men, with higher 
mortality in younger male age groups compared to women. 17 Similarly, data on COVID-
related deaths in Italy (n=31,096) demonstrates higher mortality in men than women across 
all age deciles except ≥90 years where mortality was higher than in women. 16 However, 
neither analyses provided an adjustment for age, which makes comparisons between sexes 
challenging. 
Differences in outcomes between sexes could be explained by the greater number of 
reported underlying conditions in men compared to women as demonstrated in our analysis. 
Another proposed hypothesis relates to the circulating level of angiotensin-converting 
enzyme 2 (ACE2), the main host cell receptor towards which SARS-CoV-2 has been shown 
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to have significantly high affinity, which has been shown to be greater in men than women, 
and in adults compared to children. 28 5, 29 Furthermore, women are believed to have a better 
immune response against viral infections compared with men, primarily due to higher levels 
of estrogen, which is also believed to directly suppress viral replication.7, 8, 13 The decline in 
levels of estrogen with advanced age, albeit with higher level in females throughout, could 
also explain the higher rate of mortality elder subjects. 6 
Our analysis suggests that a small proportion of COVID-19 deaths experienced acute 
events such ACS, acute stroke and pulmonary embolism, and these were lower than in non-
COVID deaths. It is difficult to compare these findings to other studies due to limited data on 
the acute conditions reported in COVID deaths from other countries, or whether there may 
have been an element of reporting bias, where acute events were reported as COVID deaths. 
Previous studies have suggested a high prevalence of certain comorbidities such as 
hypertension and ischemic heart disease in patients who died from COVID-19. 20 24, 25 30 
However, these have been mostly limited by their small sample size or analysis of selected 
cohorts (e.g. intensive care admission only). In our analysis we find that a third of individuals 
who died had no underlying chronic conditions, but there were more chronic conditions in 
COVID than non-COVID deaths, with the most prevalent reported being hypertension, 
dementia, chronic lung disease and diabetes in both groups. 
Interestingly, we find that the prevalence of ischemic heart disease in COVID-19 
related deaths is similar to that observed in non COVID-19 deaths, apart from in younger 
men (<60 years old) where paradoxically the prevalence is double that in patients that died 
non-COVID deaths. Reports from several studies have demonstrated a high prevalence of 
cardiovascular disease (CVD) in patients with COVID-19. 25 24 31 Although the underlying 
mechanisms are unclear, patients with CVD are more likely to develop severe COVID-
infection, which is attributed to multiple factors including advanced age, lower ACE2 levels 
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and impaired immunity. 32 It is also possible that pharmacological treatment administered for 
COVID infection provokes fatal arrhythmias, to which CVD patients appear to be more 
susceptible. 33 In a meta-analysis of 1576 COVID-infected patients, the most prevalent 
comorbidities were hypertension (21.1%), diabetes (9.7%) and CVD (8.4%). Their analysis 
showed that the odds ratios (OR) of hypertension and CVD were significantly higher in 
patients with severe than non-severe COVID (OR 2.36 (95% confidence interval (CI): 1.46–
3.83) and 3.42 (95% CI: 1.88–6.22), respectively). 34 However, these data may not hold true 
in patients who die from COVID, who may have greater baseline comorbidity. In a report 
from the Italian Instituto Superiore Di Sanita the prevalence of hypertension (68.3%) and 
ischemic heart disease (28.3%) was significantly higher in COVID deaths (n=31.096). 35 
Differences between countries may reflect differences in reporting methods, or 
sociodemographic and genetic differences. 
Amongst COVID deaths, acute conditions were observed to be either similar between 
sexes (pulmonary embolism) or more prevalent in men (ACS and acute stroke).  In terms of 
chronic conditions, women had higher rates of dementia, heart failure and chronic lung 
disease compared to men, whilst men had higher rates of pre-existing IHD, CKD, 
hypertension and diabetes. Notably, there was no difference in the rates of underlying cancer 
between sexes. Although the pattern of findings was consistent across age groups, certain 
differences in underlying conditions were noted. Pulmonary embolism was more frequently 
reported in <60 and 60-69 age deciles amongst COVID deaths, more so in men than women, 
whereas cancer rates were higher in younger age groups, especially in women compared to 
men. Data on 31.096 COVID deaths from Italy shows that men had a higher prevalence of 
IHD (31.7% vs. 21.3%), diabetes (30.8% vs. 28.8%) and chronic renal failure (21.5% vs. 
18.2%) and lower prevalence of heart failure (14.6% vs. 18.1%), compared to women, and 
that there was no difference in the rates of active cancer between sexes (men: 15.9% vs. 
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women: 15.6%), all of which are in line with our findings. 35 However, their report did not 
compare these conditions between age groups. 
The present findings have several important implications from a national and 
international perspective. Our comprehensive analysis adds to the body of literature on sex 
and age differences in patterns of death from a national perspective in a population with a 
high mortality rank. Furthermore, our report of underlying medical conditions in the overall 
population of COVID-19 deaths, as well as in both sexes, may help inform stakeholders’ and 
governments’ policies by identifying high-risk groups who could benefit from prolonged 
shielding, especially in the event of a second peak, and/or vaccination priority in the future. 
Limitations
 Although our study provides insights into the patterns of age and sex differences in 
COVID-19-related deaths and reported underlying medical conditions in a full nationwide 
cohort from England and Wales, there are a number of limitations. First, only conditions that 
were thought to contribute to the death are entered on the death certificate, rather than a list 
of all comorbid conditions that a patient may have. Our analysis therefore provides an 
overview of comorbid conditions that were judged by clinicians completing the death 
certificate to have contributed to death, without any external auditing, rather than a 
description of all prevalent comorbid conditions. Second, we did not have access to ethnic 
data, that may confound our analyses, particularly given that the mortality rate from COVID-
19 in Black, Asian and minority ethnic people have been reported as up to three times 
greater.36 
Conclusions
In this nationwide analysis of deaths in England and Wales between 1st March and 
12th May 2020, we demonstrate that the age-adjusted mortality of COVID-19 was higher than 
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that of other primary causes of death across all age groups and in both sexes, with the 
exception of cancer mortality in women between 30-79 years, whose adjusted-mortality was 
higher than COVID-19. Our findings also suggest persistently higher age-adjusted mortality 
in men compared to women across all age groups throughout the study period. Our report of 
underlying medical conditions in the overall population of COVID-19 deaths, as well as in 
both sexes, may help inform stakeholders’ and government body policies by identifying high-
risk groups. 
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18-29 126 0.2% 2.7 85 0.2% 1.9 211 0.2% 2.3 37 0.2% 0.8 25 0.2% 0.6 62 0.2% 0.7
30-39 297 0.6% 7.6 261 0.5% 6.6 558 0.5% 7.1 103 0.5% 2.6 72 0.5% 1.8 175 0.5% 2.2
40-49 965 1.9% 25.7 774 1.4% 20.3 1739 1.6% 23 342 1.7% 9.1 195 1.2% 5.1 537 1.5% 7.1
50-59 3005 5.8% 76.9 2158 3.9% 53.7 5163 4.8% 65.2 1204 5.8% 30.8 621 3.9% 15.5 1825 5.0% 23
60-69 6321 12.2% 207.8 4446 7.9% 139.0 10767 10.0% 172.5 2555 12.3% 84 1275 8.1% 39.9 3830 10.5% 61.4
70-79 13298 25.6% 576.1 10326 18.4% 400.7 23624 21.9% 483.6 5427 26.2% 235.1 3127 19.9% 121.3 8554 23.5% 175.1
80-89 18867 36.4% 1853.9 20233 36.1% 1452.9 39100 36.3% 1622.2 7942 38.4% 780.4 6247 39.7% 448.6 14189 38.9% 588.7
90+ 9000 17.3% 5388.9 17696 31.6% 4889.3 26696 24.8% 5047.1 3097 15.0% 1854.4 4169 26.5% 1151.8 7266 19.9% 1373.6
a ASMR: per 100,000 population
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Table 2. Frequencies and age-standardised mortality rates (ASMR) of primary causes of deaths (a ASMR: per 100,000 population).
Age group (years)
Primary cause of 
death, n (ASMRa)
18-29 30-39 40-49 50-59 60-69 70-79 80-89 90+
COVID-19
Men 37 (0.8) 103 (2.6) 342 (9.1) 1204 (30.8) 2555 (84) 5427 (235.1) 7942 (780.4) 3097 (1854.4)
Women 25 (0.6) 72 (1.8) 195 (5.1) 621 (15.5) 1275 (39.9) 3127 (121.3) 6247 (448.6) 4169 (1151.8)
Total 62 (0.7) 175 (2.2) 537 (7.1) 1825 (23) 3830 (61.4) 8554 (175.1) 14189 (588.7) 7266 (1373.6)
AKI
Men 1 (0) 0 (0) 1 (0) 8 (0.2) 23 (0.8) 63 (2.7) 108 (10.6) 36 (21.6)
Women 0 (0) 0 (0) 1 (0) 10 (0.2) 30 (0.9) 47 (1.8) 101 (7.3) 54 (14.9)
Total 1 (0) 0 (0) 2 (0) 18 (0.2) 53 (0.8) 110 (2.3) 209 (8.7) 90 (17)
PE
Men 1 (0) 17 (0.4) 23 (0.6) 73 (1.9) 135 (4.4) 149 (6.5) 98 (9.6) 20 (12)
Women 5 (0.1) 15 (0.4) 22 (0.6) 38 (0.9) 89 (2.8) 153 (5.9) 160 (11.5) 59 (16.3)
Total 6 (0.1) 32 (0.4) 45 (0.6) 111 (1.4) 224 (3.6) 302 (6.2) 258 (10.7) 79 (14.9)
Page 64 of 87
































































Underlying Conditions in COVID-19 Deaths
© 2020 Mayo Foundation for Medical Education and Research. Mayo Clin Proc. 2020;95(x):xx-xx.       19
Stroke
Men 6 (0.1) 10 (0.3) 42 (1.1) 103 (2.6) 198 (6.5) 388 (16.8) 514 (50.5) 201 (120.4)
Women 1 (0) 9 (0.2) 38 (1) 81 (2) 166 (5.2) 454 (17.6) 849 (61) 594 (164.1)
Total 7 (0.1) 19 (0.2) 80 (1.1) 184 (2.3) 364 (5.8) 842 (17.2) 1363 (56.6) 795 (150.3)
ACS
Men 0 (0) 10 (0.3) 66 (1.8) 187 (4.8) 348 (11.4) 532 (23) 486 (47.8) 127 (76)
Women 2 (0) 4 (0.1) 14 (0.4) 36 (0.9) 102 (3.2) 254 (9.9) 356 (25.6) 197 (54.4)
Total 2 (0) 14 (0.2) 80 (1.1) 223 (2.8) 450 (7.2) 786 (16.1) 842 (34.9) 324 (61.3)
Acute respiratory 
failure
Men 2 (0) 5 (0.1) 8 (0.2) 41 (1) 78 (2.6) 152 (6.6) 124 (12.2) 33 (19.8)
Women 3 (0.1) 5 (0.1) 11 (0.3) 31 (0.8) 74 (2.3) 162 (6.3) 141 (10.1) 47 (13)
Total 5 (0.1) 10 (0.1) 19 (0.3) 72 (0.9) 152 (2.4) 314 (6.4) 265 (11) 80 (15.1)
Respiratory infections
Men 23 (0.5) 24 (0.6) 82 (2.2) 258 (6.6) 733 (24.1) 2181 (94.5) 3841 (377.4) 2035 (1218.5)
Women 7 (0.2) 24 (0.6) 61 (1.6) 209 (5.2) 539 (16.8) 1523 (59.1) 3508 (251.9) 3054 (843.8)
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Total 30 (0.3) 48 (0.6) 143 (1.9) 467 (5.9) 1272 (20.4) 3704 (75.8) 7349 (304.9) 5089 (962.1)
Other infections
Men 7 (0.2) 9 (0.2) 26 (0.7) 77 (2) 170 (5.6) 491 (21.3) 814 (80) 346 (207.2)
Women 5 (0.1) 11 (0.3) 26 (0.7) 61 (1.5) 145 (4.5) 381 (14.8) 829 (59.5) 584 (161.3)
Total 12 (0.1) 20 (0.3) 52 (0.7) 138 (1.7) 315 (5) 872 (17.8) 1643 (68.2) 930 (175.8)
Chronic lung disease
Men 0 (0) 0 (0) 8 (0.2) 41 (1) 151 (5) 373 (16.2) 284 (27.9) 67 (40.1)
Women 0 (0) 0 (0) 6 (0.2) 38 (0.9) 139 (4.3) 346 (13.4) 283 (20.3) 92 (25.4)
Total 0 (0) 0 (0) 14 (0.2) 79 (1) 290 (4.6) 719 (14.7) 567 (23.5) 159 (30.1)
Old age (senility)
Men 0 (0) 0 (0) 0 (0) 0 (0) 1 (0) 27 (1.2) 906 (89) 1224 (732.9)
Women 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 36 (1.4) 1440 (103.4) 3288 (908.4)
Total 0 (0) 0 (0) 0 (0) 0 (0) 1 (0) 63 (1.3) 2346 (97.3) 4512 (853)
Dementia
Men 0 (0) 0 (0) 0 (0) 7 (0.2) 70 (2.3) 543 (23.5) 1589 (156.1) 710 (425.1)
Women 0 (0) 0 (0) 1 (0) 17 (0.4) 94 (2.9) 710 (27.6) 2736 (196.5) 2383 (658.4)
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Total 0 (0) 0 (0) 1 (0) 24 (0.3) 164 (2.6) 1253 (25.6) 4325 (179.4) 3093 (584.7)
Heart Failure
Men 2 (0) 8 (0.2) 38 (1) 119 (3) 285 (9.4) 646 (28) 1023 (100.5) 471 (282)
Women 1 (0) 4 (0.1) 17 (0.4) 43 (1.1) 98 (3.1) 408 (15.8) 884 (63.5) 628 (173.5)
Total 3 (0) 12 (0.2) 55 (0.7) 162 (2) 383 (6.1) 1054 (21.6) 1907 (79.1) 1099 (207.8)
CKD
Men 0 (0) 0 (0) 2 (0.1) 18 (0.5) 38 (1.2) 72 (3.1) 128 (12.6) 46 (27.5)
Women 1 (0) 1 (0) 0 (0) 6 (0.1) 25 (0.8) 45 (1.7) 104 (7.5) 22 (6.1)
Total 1 (0) 1 (0) 2 (0) 24 (0.3) 63 (1) 117 (2.4) 232 (9.6) 68 (12.9)
Cancers
Men 11 (0.2) 82 (2.1) 254 (6.8) 962 (24.6) 2086 (68.6) 3724 (161.3) 3393 (333.4) 862 (516.1)
Women 14 (0.3) 103 (2.6) 321 (8.4) 970 (24.2) 1815 (56.7) 3175 (123.2) 3011 (216.2) 906 (250.3)
Total 25 (0.3) 185 (2.3) 575 (7.6) 1932 (24.4) 3901 (62.5) 6899 (141.2) 6404 (265.7) 1768 (334.2)
Other causes
Men 73 (1.6) 132 (3.4) 415 (11.1) 1111 (28.4) 2005 (65.9) 3957 (171.4) 5559 (546.2) 2822 (1689.7)
Women 46 (1) 85 (2.1) 256 (6.7) 618 (15.4) 1130 (35.3) 2632 (102.1) 5831 (418.7) 5788 (1599.1)
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Total 119 (1.3) 217 (2.8) 671 (8.9) 1729 (21.8) 3135 (50.2) 6589 (134.9) 11390 (472.6) 8610 (1627.7)
Page 68 of 87
































































Underlying Conditions in COVID-19 Deaths
© 2020 Mayo Foundation for Medical Education and Research. Mayo Clin Proc. 2020;95(x):xx-xx.       23
















Age, median (IQR) 81 (72, 87) 85 (76, 91) 83 (74, 89) <.001 80 (72, 87) 84 (76, 90) 82 (73, 88) <.001
Month of death, n (row %) <.001 <.001
March 23564 (49.9) 23649 (50.1) 47213 2804 (61.7) 1739 (38.3) 4543
April 23591 (46.9) 26687 (53.1) 50278 16221 (56.8) 12335 (43.2) 28556
Maya 4724 (45.6) 5644 (54.4) 10368 1682 (50.4) 1657 (49.6) 3339
Number of reported chronic 
underlying conditions <.001 <.001
0 14821 (28.6) 17388 (31.1) 32209 (29.9) 6318 (30.5) 5287 (33.6) 11605 (31.8)
1 21904 (42.2) 25225 (45.1) 47129 (43.7) 7501 (36.2) 6028 (38.3) 13529 (37.1)
2 9729 (18.8) 9071 (16.2) 18800 (17.4) 4537 (21.9) 2965 (18.8) 7502 (20.6)
≥3 5425 (10.5) 4296 (7.7) 9721 (9) 2351 (11.4) 1451 (9.2) 3802 (10.4)
Chronic conditions
Pre-existing Ischaemic Heart 
Disease, n (%) 8114 (15.6) 4799 (8.6) 12913 (12) <.001 2918 (14.1) 1235 (7.9) 4153 (11.4) <.001
Heart Failure, n (%) 5907 (11.4) 5312 (9.5) 11219 (10.4) <.001 1609 (7.8) 1301 (8.3) 2910 (8) .08
Dementia, n (%) 6620 (12.8) 10490 (18.7) 17110 (15.9) <.001 3523 (17) 3328 (21.2) 6851 (18.8) <.001
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Chronic Kidney Disease, n (%) 4173 (8) 4099 (7.3) 8272 (7.7) <.001 2354 (11.4) 1500 (9.5) 3854 (10.6) <.001
Hypertension, n (%) 5655 (10.9) 6407 (11.4) 12062 (11.2) .005 4171 (20.1) 2740 (17.4) 6911 (19.0) <.001
Chronic Lung Disease, n (%) 6550 (12.6) 5755 (10.3) 12305 (11.4) <.001 3125 (15.1) 2559 (16.3) 5684 (15.6) .002
Diabetes, n (%) 4833 (9.3) 3937 (7) 8770 (8.1) <.001 3531 (17.1) 2020 (12.8) 5551 (15.2) <.001
Liver Disease, n (%) 1516 (2.9) 895 (1.6) 2411 (2.2) <.001 278 (1.3) 182 (1.2) 460 (1.3) .12
Peripheral Vascular Disease, n (%) 1189 (2.3) 854 (1.5) 2043 (1.9) <.001 357 (1.7) 130 (0.8) 487 (1.3) <.001
Valvular Heart Disease, n (%) 1019 (2) 881 (1.6) 1900 (1.8) <.001 273 (1.3) 202 (1.3) 475 (1.3) .78
Cancers, n (%) 12475 (24) 12745 (22.8) 25220 (23.4) <.001 1615 (7.8) 1216 (7.7) 2831 (7.8) .81
Acute conditions
Strokeb, n (%) 3620 (7) 4309 (7.7) 7929 (7.4) <.001 1287 (6.2) 839 (5.3) 2126 (5.8) <.001
Major Bleeding, n (%) 1585 (3.1) 1575 (2.8) 3160 (2.9) .02 218 (1.1) 120 (0.8) 338 (0.9) .004
Pulmonary embolism, n (%) 932 (1.8) 1027 (1.8) 1959 (1.8) .64 280 (1.4) 181 (1.2) 461 (1.3) .09
Acute Coronary Syndrome, n (%) 2614 (5) 1529 (2.7) 4143 (3.8) <.001 307 (1.5) 137 (0.9) 444 (1.2) <.001
Infective Endocarditis, n (%) 390 (0.8) 343 (0.6) 733 (0.7) .005 85 (0.4) 80 (0.5) 165 (0.5) .17
a Correct as of 12th May 2020
b Includes bleeding and ischaemic strokes
IQR: interquartile range
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Figure 1. Distribution of Covid-19 deaths in England and Wales from the start of the pandemic 
through 12th May 2020 according to sex. ACS: acute coronary syndrome; CKD: chronic kidney 
disease: IHD: ischaemic heart disease; PE: pulmonary embolism.
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2A
2B
Figure 2. Age standardized mortality rate according to COVID status (per 100,000 population). ACS: 
acute coronary syndrome; CKD: chronic kidney disease: IHD: ischaemic heart disease; PE: 
pulmonary embolism.
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Figure 3. Number of reported underlying chronic conditions in the overall cohort and according to 
COVID status and sex. ACS: acute coronary syndrome; CKD: chronic kidney disease: IHD: 
ischaemic heart disease; PE: pulmonary embolism.
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Figure 4. Top reported conditions associated with COVID and non-COVID deaths in England and 
Wales in overall cohort and according to sex and age group. ACS: acute coronary syndrome; CKD: 
chronic kidney disease: IHD: ischaemic heart disease; PE: pulmonary embolism.
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Sex-differences in Mortality Rates and Underlying Conditions for COVID-19 Deaths in 
England and Wales
Online Supplementary Material 
- Table S1. List of ICD-10 CM diagnosis codes used in the study
- Table S2. Rates of COVID-19 deaths per county region according to sex
- Table S3. Characteristics and reported underlying conditions of deceased patients A) without and B) 
with COVID -19 according to sex and age group
- Figure S1. Distribution of Covid-19 deaths in England and Wales according to sex
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Table S1. List of ICD-10 CM* diagnosis codes used in the study
Diagnosis Codes
COVID-19 U07.1
Pre-existing Ischaemic Heart 
Disease
I25.2, I25.6, Z98.61, I25.10, I25.110, I25.111, I25.118, 
I25.119, I25.7*, I25.8*, I25.9*, Z95.1
Heart Failure I50*, I42*, I25.5
Dementia F01*, F02*, F03*
Chronic Kidney Disease N18*
Hypertension I10*
Chronic Lung Disease J41*, J42*, J43*, J44*, J45*, J47*
Diabetes E08*, E09*, E10*, E11*, E13*
Liver Disease K70*, K72.1*, K72.9*, K73*, K74*, K75*, K76*, K77*
Peripheral Vascular Disease I70*, I73*
Valvular Heart Disease I34*, I35*, I36*, I37*
Cancers C00-C96*
Stroke G46.3, G46.4, G46.5, G46.6, G46.7, I60*, I61*, I62*, I63*, I64*
Major Bleeding
I60*, I61*, I62*, R58, K92.0, K92.1, K92.2, K25.0, 
K25.1, K25.2, K25.4, K25.5, K25.6, K26.0, K26.1, 
K26.2, K26.4, K26.5, K266, K27.0, K27.1, K27.2, K27.4, 
K27.5, K27.6, K28.0, K28.1, K28.2, K28.4, K28.5, K28.6
Pulmonary embolism I26*
Acute Coronary Syndrome I20*, I21*, I22*
Infective Endocarditis I33*, I38*, I39*
*International Classification of Diseases, tenth revision (ICD-10)
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Table S2. Rates of COVID-19 deaths per county region according to sex
County Men Women Total
Bedfordshire 267 (1.3%) 168 (1.1%) 435 (1.2%)
Berkshire 298 (1.4%) 271 (1.7%) 569 (1.6%)
Bristol 152 (0.7%) 114 (0.7%) 266 (0.7%)
Buckinghamshire 204 (1%) 190 (1.2%) 394 (1.1%)
Cambridgeshire 201 (1%) 141 (0.9%) 342 (0.9%)
Cheshire 422 (2.1%) 341 (2.2%) 763 (2.1%)
Cornwall 91 (0.4%) 46 (0.3%) 137 (0.4%)
Cumbria 191 (0.9%) 165 (1.1%) 356 (1%)
Derbyshire 337 (1.6%) 270 (1.7%) 607 (1.7%)
Devon 166 (0.8%) 128 (0.8%) 294 (0.8%)
Dorset 54 (0.3%) 39 (0.2%) 93 (0.3%)
Durham 317 (1.5%) 302 (1.9%) 619 (1.7%)
East Sussex 161 (0.8%) 127 (0.8%) 288 (0.8%)
East York 146 (0.7%) 78 (0.5%) 224 (0.6%)
Essex 745 (3.6%) 505 (3.2%) 1250 (3.5%)
Gloucestershire 269 (1.3%) 235 (1.5%) 504 (1.4%)
Hampshire 493 (2.4%) 364 (2.3%) 857 (2.4%)
Hertfordshire 452 (2.2%) 364 (2.3%) 816 (2.3%)
Isle of Wight 21 (0.1%) 22 (0.1%) 43 (0.1%)
Kent 535 (2.6%) 407 (2.6%) 942 (2.6%)
Lancashire 275 (1.3%) 182 (1.2%) 457 (1.3%)
Lancashire 174 (0.8%) 139 (0.9%) 313 (0.9%)
Leicestershire 257 (1.3%) 211 (1.4%) 468 (1.3%)
Lincolnshire 154 (0.7%) 113 (0.7%) 267 (0.7%)
London 4519 (22%) 2991 (19.1%) 7510 (20.8%)
Manchester 1256 (6.1%) 1023 (6.5%) 2279 (6.3%)
Merseyside 752 (3.7%) 578 (3.7%) 1330 (3.7%)
Norfolk 235 (1.1%) 149 (1%) 384 (1.1%)
North Yorkshire 370 (1.8%) 297 (1.9%) 667 (1.8%)
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Northampton 216 (1.1%) 176 (1.1%) 392 (1.1%)
Northumberland 118 (0.6%) 97 (0.6%) 215 (0.6%)
Nottinghamshire 367 (1.8%) 311 (2%) 678 (1.9%)
Oxfordshire 221 (1.1%) 183 (1.2%) 404 (1.1%)
Rutland <15 (0%)* <15 (0%)* <15 (0%)*
Shropshire 117 (0.6%) 95 (0.6%) 212 (0.6%)
Somerset 102 (0.5%) 62 (0.4%) 164 (0.5%)
South Yorkshire 460 (2.2%) 430 (2.8%) 890 (2.5%)
Stafford 336 (1.6%) 276 (1.8%) 612 (1.7%)
Suffolk 184 (0.9%) 140 (0.9%) 324 (0.9%)
Surrey 547 (2.7%) 436 (2.8%) 983 (2.7%)
Tyne & Wear 432 (2.1%) 426 (2.7%) 858 (2.4%)
Wales 810 (3.9%) 638 (4.1%) 1448 (4%)
Warwick 213 (1%) 161 (1%) 374 (1%)
West Midlands 1543 (7.5%) 1113 (7.1%) 2656 (7.3%)
West Sussex 176 (0.9%) 144 (0.9%) 320 (0.9%)
West Yorkshire 795 (3.9%) 614 (3.9%) 1409 (3.9%)
Wiltshire 194 (0.9%) 168 (1.1%) 362 (1%)
Worcestershire 211 (1%) 196 (1.3%) 407 (1.1%)
*Exact number not revealed for confidentiality purposes
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a Includes bleeding and ischaemic strokes
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n (%) 6 (0.4) 5 (0.5)
11 














a Includes bleeding and ischaemic strokes
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Figure S1. Distribution of Covid-19 deaths in England and Wales in A) Men and B) Women*
A)
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B)
*Start of pandemic through 12th May 2020
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